Application and short-term effect of enhanced recovery after surgery on robotic distal gastric cancer surgery

shan Liu, chun wang, zhaodong xing, yuna wang, Guohao Cai, ping huangResearch Square 2022 · DOI

This study, conducted by researchers at Hainan General Hospital, explores the synergy between high-tech robotic surgery and optimized perioperative care. By applying Enhanced Recovery After Surgery (ERAS) protocols to robotic distal gastrectomy (RDG) for gastric cancer, the authors demonstrate that patient recovery can be significantly accelerated, inflammatory stress reduced, and hospital costs lowered without compromising surgical safety.

TL;DR

This paper evaluates the impact of combining Enhanced Recovery After Surgery (ERAS) protocols with robotic distal gastrectomy for gastric cancer. The results show that ERAS significantly shortens hospital stays, reduces post-operative inflammation and costs, and speeds up the return of gastrointestinal function compared to traditional care.

What Problem Does This Paper Address?

Gastric cancer remains a leading cause of cancer-related mortality, particularly in China. While surgical intervention has evolved from open surgery to minimally invasive laparoscopic and now robotic-assisted techniques (like the Da Vinci system), the surgery itself is only part of the equation.

The "stress" of surgery—including long fasting periods, invasive tubes, and delayed movement—can slow down recovery. Enhanced Recovery After Surgery (ERAS) is a multimodal framework designed to minimize this stress. While ERAS is well-established in laparoscopic surgery, its specific efficacy and feasibility when paired with the high precision of robotic distal gastrectomy (RDG) required more clinical validation. This paper seeks to fill that gap.

Methods

The researchers conducted a retrospective study of 52 patients treated between July 2020 and January 2022. The patients were divided into two equal groups:

  1. ERAS Group (Eg): Followed a protocol including preoperative counseling, shortened fasting (solid food 6h before, water 2h before), no routine nasogastric tubes, multi-mode analgesia to reduce opioid use, and early mobilization (walking on day one).
  2. Regulation Nursing Group (Rng): Followed traditional perioperative care, including longer fasting periods, routine use of nasogastric tubes, and later mobilization.

The study compared "general data" (age, BMI) to ensure groups were comparable, and then measured "perioperative data," including C-reactive protein (a marker for inflammation), time to first flatus (gas), hospital stay duration, and total medical expenses.

Datasets

The study utilized a clinical dataset of 52 patients from the Department of General Surgery at Hainan General Hospital, Haikou, China.

  • Inclusion Criteria: Confirmed gastric cancer, normal cardiopulmonary function, and eligibility for robotic surgery.
  • Exclusion Criteria: History of abdominal surgery, preoperative radiotherapy/chemotherapy, or age > 80.

Key Insights and Ideas

  • Surgical Independence: There was no significant difference in operation time, blood loss, or the number of lymph nodes dissected between the two groups. This suggests that ERAS protocols do not interfere with the technical execution or oncological quality of the robotic surgery.
  • Blunting the Stress Response: Post-operative C-reactive protein (CRP) levels were significantly lower in the ERAS group (10.45 vs. 18.44 mg/L). This indicates that the ERAS protocol successfully mitigated the systemic inflammatory response triggered by surgery.
  • Functional Fast-Tracking: The ERAS group achieved "anal exhaust" (a key indicator of gut function recovery) and started liquid intake significantly sooner than the control group.
  • Economic Efficiency: ERAS led to a significant reduction in hospitalization expenses (approximately 10,000 RMB less on average), proving that better care can also be more cost-effective.

Key Results

The quantitative advantages of the ERAS + Robotic approach were clear ($P < 0.05$ for all the following):

  • Hospital Stay: Reduced from 11.33 days (Control) to 9.31 days (ERAS).
  • Ambulation Time: Patients in the ERAS group were walking after 1.19 days, compared to 2.77 days in the control group.
  • Inflammation: Post-operative CRP was nearly 43% lower in the ERAS group.
  • Cost: Average hospitalization expenses dropped from 80,951 RMB to 70,801 RMB.
  • Complications: While the ERAS group had fewer total complications (3 vs. 5), this specific metric did not reach statistical significance, likely due to the small sample size.

Limitations and Future Work

The authors acknowledge several limitations:

  • Sample Size: The study only included 52 patients, which limits the statistical power, especially regarding complication rates.
  • Study Design: As a retrospective study from a single center, there is a risk of selection bias.
  • Long-term Data: The study focused on short-term recovery (up to 180 days). It does not yet provide data on long-term survival or cancer recurrence rates.

Future Work: The authors call for high-quality, multicenter randomized controlled trials (RCTs) with larger cohorts and long-term follow-up to more precisely evaluate the oncological outcomes of ERAS in robotic gastric surgery.

Summary updated

Abstract

<title>Abstract</title> Backgroud Robotic distal gastrectomy (RDG) has been increasingly used for the treatment of gastric cancer (GC). At the same time, enhanced recovery after surgery(ERAS) [1]has been increasing used in all kinds of operations. However,how the clinical effect of ERAS combined with RDG yet to be researched more. Thus, this study aimed to To evaluate the feasibility and efficacy of Robotic distal gastrectomy (RDG) and enhanced recovery after surgery(ERAS)[2] Methods In total, 52 patients were enrolled between July 2020 and January 2022 in this retrospective study.26 patients underwent Robotic distal gastrectomy (RDG) was adopted with routine perioperative intervention while 26 patients adopted the ERAS mode.the general date(age,gender,BMI index,underlying disease),perioperative data(operationg methods postoperative hospital stay,postoperative inflammation:C-reactive protein,postoperative ambulation time,postoperative liq-uid food intake time,postoperative anal exhaust time,operation time,the number of lymph node dissection,intraoperative blood loss, hospitalization expenses,postoperative hospital stay), postoperative complication were compared between the two groups. Results There is no different significantly in the general date ,operation time,the number of lymph node dissection, intraoperative blood loss between this two groups(p &gt; 0.05), ERAS [3]concept showed its advantages in release postoperative inflammation,reduce postoperative hospitalization stay and cost,cut down postoperative anal exhaust time ,reduce postoperative complication (P &lt; 0. 01). Conclusions Collectively, ERAS results in accelerated convalescence, reduction of surgical stress and medical costs, improved nutritional status, and better quality of life for gastric cancer patients. However, high-quality multicenter randomized controlled trials with large samples and long-term follow-up are needed to more precisely evaluate ERAS in RDG.
BibTeX
@inproceedings{liu2022application,
  author = {shan Liu and chun wang and zhaodong xing and yuna wang and Guohao Cai and ping huang},
  title = {{Application and short-term effect of enhanced recovery after surgery on robotic distal gastric cancer surgery}},
  booktitle = {Research Square},
  year = {2022},
  doi = {10.21203/rs.3.rs-1698602/v1},
}
Figure